Cerebral Palsy: Disease-Characteristics Research Report

Executive summary

Cerebral palsy (CP) is not one etiologic disease but a clinically defined, heterogeneous group of permanent movement and posture disorders caused by a non-progressive disturbance of the developing fetal or infant brain. The original lesion does not progress, although musculoskeletal complications, pain, fatigue, and functional limitations may change across life. Current evidence rejects the older assumption that CP is principally synonymous with intrapartum asphyxia: prematurity, congenital maldevelopment, stroke, infection/inflammation, placental disease, neonatal injury, and an increasingly important genomic component all contribute. A 2024 review reports prevalence of approximately 1.6 per 1,000 live births in high-income countries versus 3.3 per 1,000 in low- and middle-income countries. Common associated impairments include cognitive impairment (~50%), epilepsy (~33%), language impairment (~33%), and inability to walk independently (~40%). (xu2024geneticpathwaysin pages 1-1)

The most important recent development is genomic reclassification. A 2024 Nature Genetics study of 327 parent-child trios identified pathogenic/likely pathogenic variants in 37 children (11%) and variants of uncertain significance in 58 (18%). A separate meta-analytic estimate cited in a 2024 eBioMedicine review was 23% for single-nucleotide variants and 5% for copy-number variants. Thus, CP remains a clinical syndrome, but a molecular diagnosis can refine recurrence risk, prognosis, surveillance, and occasionally treatment. (fehlings2024comprehensivewholegenomesequence pages 26-28, fehlings2024comprehensivewholegenomesequence pages 17-19, lewis2024potentialclinicalapplications pages 1-2)

The following compact knowledge-base summary precedes the detailed report.

Table: This compact table summarizes high-confidence, evidence-backed facts for a cerebral palsy knowledge-base entry, spanning definition, phenotypes, epidemiology, genetics, diagnosis, treatment, prognosis, and models. It distinguishes established care from experimental approaches and includes ontology suggestions for structured annotation.

1. Disease information

Definition and classification

The accepted construct is a group of permanent disorders of movement and posture causing activity limitation, attributable to non-progressive disturbances in the developing fetal or infant brain. “Permanent” describes the motor disorder; “non-progressive” describes the causal brain disturbance—not the person’s changing phenotype. CP may be spastic, dyskinetic, ataxic, hypotonic, or mixed and may be unilateral or bilateral. Function is classified separately with the five-level Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System (CFCS), and Eating and Drinking Ability Classification System (EDACS). (xu2024geneticpathwaysin pages 1-1, xu2024geneticpathwaysin pages 2-3)

Identifiers and synonyms

• MONDO: MONDO:0006497.
• MeSH: D002547, Cerebral Palsy.
• ICD-10-CM: G80.-; important descendants include G80.0 spastic quadriplegic CP, G80.1 spastic diplegic CP, G80.2 spastic hemiplegic CP, G80.3 dyskinetic CP, G80.4 ataxic CP, G80.8 other CP, and G80.9 unspecified CP.
• ICD-11: under cerebral palsy in developmental motor disorders; implementation-specific codes should be verified against the current national ICD-11 release.
• OMIM/Orphanet: no single disease-wide Mendelian entry adequately represents CP because it is a descriptive syndrome; individual genetic CP/CP-mimic disorders have separate entries.
• Synonyms: infantile cerebral palsy, cerebral palsies, static encephalopathy (the latter is broader and potentially misleading), spastic diplegia/hemiplegia/quadriplegia when subtype-specific.

Open Targets recognizes MONDO:0006497 and associates CP-related evidence with genes including SPAST, COL4A1, SNAP25, PMM2, and with AP-4-complex genes in spastic quadriplegic CP; these associations mix causal-disease and therapeutic-target evidence and therefore must not all be interpreted as disease-causing CP genes. (OpenTargets Search: cerebral palsy)

Data provenance: the report concerns aggregated disease-level evidence from cohorts, registries, trials, and reviews. Individual EHR observations can establish a patient’s phenotype but are not the source of the disease-level assertions here.

2. Etiology

CP is best represented as an endpoint reached through multiple causal routes.

Acquired and developmental factors

A 2023 systematic review identified 40 repeatedly reported determinants across 95 studies. Prematurity/low birth weight appeared in 24 studies and low Apgar score in 15. Other recurring factors were intrauterine infection, congenital brain malformation, premature rupture of membranes, placental abruption, maternal thyroid disease, fetal growth restriction, multiple gestation, neonatal CNS infection, stroke, and severe hyperbilirubinemia. Perinatal asphyxia was estimated to account for fewer than 10–20% of cases, emphasizing that temporal proximity to delivery does not prove intrapartum causation. (tegegne2023determinantsofcerebral pages 1-2)

Risk categories include:

• Preconception/maternal: diabetes, epilepsy, thyroid disease, obesity, anemia, hypertension and pre-eclampsia; extremes of maternal age and assisted reproduction can mark increased risk but are not individually deterministic.
• Placental/fetal: inflammation or infection, placental abruption/vascular malperfusion, congenital brain malformation, fetal growth restriction, multiple pregnancy, and fetal stroke.
• Perinatal/neonatal: extreme prematurity, very low birth weight, intraventricular hemorrhage, periventricular white-matter injury, neonatal encephalopathy/HIE, sepsis/meningitis, severe jaundice/kernicterus, hypoglycemia, and cardiorespiratory instability.
• Postneonatal: traumatic brain injury, CNS infection, stroke, drowning/hypoxia, and untreated status epilepticus during the early developmental period.

Genetic factors and gene-environment interaction

Genetic etiologies include de novo dominant variants, autosomal-recessive disorders, X-linked disorders, mitochondrial variants, and CNVs. A genetic lesion may cause maldevelopment directly, predispose to thrombosis or stroke (PROC, COL4A1/COL4A2), alter neuronal migration or axonal transport (CTNNB1, KIF1A, L1CAM, TUBA1A), or impair mitochondrial metabolism. Genetics may also modify vulnerability to environmental injury. Maternal inflammation can prime fetal microglia and amplify damage from a subsequent hypoxic-ischemic insult—the experimentally supported “two-hit” model. (xu2024geneticpathwaysin pages 1-1, collins2024theimportanceof pages 1-2, lewis2024potentialclinicalapplications pages 1-2)

Protective factors

No validated common protective human allele prevents CP. Established environmental/clinical protection is chiefly obstetric and neonatal: prevention of preterm birth and infection; antenatal corticosteroids when preterm delivery is expected; magnesium sulfate for fetal neuroprotection; caffeine in selected ventilated preterm infants; prompt resuscitation and treatment of jaundice, hypoglycemia and infection; and therapeutic hypothermia for eligible term/near-term infants with moderate-to-severe HIE. A major systematic review estimated approximately 30% prevention with antenatal magnesium sulfate in very-preterm populations and approximately 15% prevention of hypoxia-associated CP with timely hypothermia. (novak2020stateofthe pages 4-6)

3. Phenotypes

Motor manifestations begin in infancy or early childhood and vary from mild unilateral fine-motor impairment to profound four-limb and bulbar disability. The causal lesion is stable, but manifestations evolve with growth.

• Spasticity—velocity-dependent hypertonia, hyperreflexia, clonus; severity variable. Suggested HPO: HP:0001257.
• Motor-development delay—late head control, sitting, crawling or walking; infancy. HP:0001270.
• Abnormal gait/toe walking/scissoring—primarily ambulant spastic CP. HP:0001288 (gait disturbance), HP:0002061 (lower-limb spasticity).
• Dystonia/choreoathetosis—fluctuating postures and involuntary movement, especially dyskinetic CP. HP:0001332, HP:0002071.
• Ataxia/tremor/dysmetria—usually childhood-recognized and non-degenerative. HP:0001251.
• Unilateral weakness/asymmetry—hemiplegic CP, often after perinatal stroke. HP:0004374 or laterality-specific weakness terms.
• Oromotor dysfunction, dysphagia, drooling—severity tracks motor impairment; affects nutrition, aspiration risk and participation. HP:0002015, HP:0002307.
• Speech/language impairment—approximately one-third in a 2024 synthesis. HP:0000750, HP:0002465 (dysarthria). (xu2024geneticpathwaysin pages 1-1)
• Intellectual/developmental impairment—approximately 50%; highly variable. HP:0001249, HP:0001263.
• Epilepsy—approximately one-third; more frequent with cortical injury and severe bilateral CP. HP:0001250. (xu2024geneticpathwaysin pages 1-1)
• Visual/hearing impairment, pain, sleep disorder, constipation, reflux, scoliosis, hip displacement, contractures and low bone density are important associated or secondary phenotypes.

In a relatively unselected Slovenian cohort, 85% had spastic, 13% dyskinetic and 2% ataxic CP; 36% were GMFCS I. (silan2025unravellinggeneticetiology pages 1-2)

Quality of life: pain, communication barriers, feeding dependence, fatigue, reduced mobility and inaccessible environments can restrict education, employment, relationships and community participation. Quality of life is not reducible to GMFCS: communication, pain, autonomy, family support and environmental inclusion are major modifiers. Disease-specific instruments include CP-QOL; generic tools include EQ-5D-Y, PedsQL, PROMIS and adult SF-36.

4. Genetic and molecular information

Architecture and implicated genes

CP has no single canonical causal gene. More than 100 recurrent genes have been reported, converging on axon guidance, synaptic function, vesicle transport, transcription, neuronal migration, thrombosis/angiogenesis, mitochondrial oxidative phosphorylation and autophagy. (xu2024geneticpathwaysin pages 1-1, lewis2024potentialclinicalapplications pages 1-2)

Examples include CTNNB1, SPAST, ATL1, KIF1A, L1CAM, AP4B1, AP4E1, AP4M1, AP4S1, COL4A1, COL4A2, PROC, GNAO1, KCNQ2, TUBB4A, TUBA1A, PDHA1, FAR1, PLA2G6, SYNGAP1, ZC4H2, ZSWIM6, and mitochondrial genes. These genes span dominant, recessive, X-linked and mitochondrial inheritance. They should be annotated to their specific molecular diagnoses rather than treated as interchangeable “CP genes.” (silan2025unravellinggeneticetiology pages 1-2, xu2024geneticpathwaysin pages 8-9, yigit2026unmaskinggeneticetiologies pages 1-2)

In the 2024 WGS study, 37/327 children (11%) had pathogenic/likely pathogenic variants and 58/327 (18%) had VUS. Cognitive impairment was more frequent in the P/LP group (49%) than in VUS (33%) or no-variant groups (22%; p=0.01). Mitochondrial variants included MT-TQ, MT-TS1, and MT-ND5. (fehlings2024comprehensivewholegenomesequence pages 17-19)

Variant interpretation

Reported pathogenic classes include loss-of-function nonsense, frameshift and splice variants; missense variants with loss-, gain-, or altered-channel function; CNVs; structural variants; and mitochondrial variants. Most severe monogenic findings are rare or absent from population databases. Allele frequency and ACMG/AMP classification must be recorded variant-by-variant from the current ClinVar and gnomAD release; no valid disease-wide allele frequency exists. VUS must not direct irreversible treatment or reproductive decisions without further evidence.

Modifiers, chromosomal and epigenetic findings

CNVs contribute an estimated ~5% diagnostic yield. Reported abnormalities include pathogenic deletions/duplications, but no single recurrent cytogenetic lesion defines CP. Epigenetic and methylation differences have been reported—including discordant monozygotic-twin studies—but causal direction and clinical utility remain unestablished. No validated modifier gene or methylation biomarker currently predicts severity in routine practice. (xu2024geneticpathwaysin pages 9-9, lewis2024potentialclinicalapplications pages 1-2)

5. Environmental information

Relevant exposures are principally developmental rather than adult lifestyle or occupational exposures. Maternal smoking, substance exposure, malnutrition, inadequate prenatal care, infection, obesity and socioeconomic disadvantage may alter risk through prematurity, fetal growth, placental function and access to care, but confounding is substantial. Environmental pollution and specific toxins are not established as direct common causes of CP.

Infectious contributors include maternal/fetal cytomegalovirus, toxoplasmosis, rubella, Zika virus and chorioamnionitis, and postnatal meningitis/encephalitis. Infection may cause direct neurotropism, malformation, vascular injury, or cytokine-mediated sensitization to hypoxia. Maternal or amniotic infection is a recognized risk factor for HIE, and maternal immune activation can produce persistent neuroimmune priming in models. (collins2024theimportanceof pages 1-2)

6. Mechanism and pathophysiology

Acquired-injury causal chain

Placental failure, infection, stroke or hypoxia-ischemia → reduced oxygen/glucose delivery → ATP depletion and anaerobic lactate accumulation → Na+/K+-pump failure and depolarization → glutamate excitotoxicity and intracellular Ca²⁺ accumulation → mitochondrial dysfunction, reactive oxygen species and protease activation → necrosis/apoptosis → secondary microglial/astrocytic inflammation → impaired oligodendrocyte maturation, myelination, axonal connectivity and neuronal circuit development → persistent motor-network dysfunction. Primary energy failure is upstream; delayed excitotoxic, oxidative and inflammatory injury is downstream and supplies a therapeutic window. (collins2024theimportanceof pages 1-2)

Preterm brains are especially vulnerable in cerebral white matter and pre-oligodendrocytes; term HIE more often injures deep gray nuclei, thalamus, perirolandic cortex, hippocampus or watershed cortex depending on insult pattern. Motor manifestations then arise from altered corticospinal, basal-ganglia-thalamocortical, cerebellar, sensory and spinal networks.

Genetic causal chains

Examples are COL4A1/PROC dysfunction → vascular fragility or thrombosis → fetal/perinatal stroke → unilateral spastic CP; tubulin/cytoskeletal defects → abnormal neuronal migration/axon formation → cortical malformation → motor impairment and epilepsy; and mitochondrial/pyruvate-metabolism defects → energy failure in vulnerable neurons → CP-like motor syndrome. Some genetic disorders are progressive and therefore CP mimics rather than CP itself.

Suggested GO processes: inflammatory response (GO:0006954), response to oxidative stress (GO:0006979), apoptotic process (GO:0006915), autophagy (GO:0006914), neuron migration (GO:0001764), axon guidance (GO:0007411), synaptic vesicle cycle (GO:0099504), myelination (GO:0042552), mitochondrial respiratory-chain complex assembly (GO:0033108), and angiogenesis (GO:0001525).

Cell Ontology suggestions: neuron (CL:0000540), cortical neuron, upper motor neuron, microglial cell (CL:0000129), astrocyte (CL:0000127), oligodendrocyte (CL:0000128), oligodendrocyte precursor cell, brain vascular endothelial cell and pericyte.

Molecular profiling and advanced technology

Transcriptomic, proteomic, metabolomic and methylomic studies report inflammatory, oxidative, lipid/myelin and energy-metabolism signatures, but none is a validated diagnostic test. The 2024 genomic review highlights long-read WGS, transcriptomics, epigenomics and improved structural/repeat-variant detection as routes for unresolved cases. Single-cell and spatial studies are mechanistically promising but not yet mature enough to define a universal CP cell atlas or clinical signature. (lewis2024potentialclinicalapplications pages 1-2)

7. Anatomical structures affected

The primary organ is the developing CNS. MRI patterns include maldevelopment, predominant white-matter injury, predominant gray-matter injury, miscellaneous lesions, or normal imaging. MRI is abnormal in more than 80% overall in cited series; one classification study attributed approximately 49% to white-matter injury, 21% to predominant gray-matter injury and 11% to maldevelopment. (lewis2024potentialclinicalapplications pages 1-2)

Suggested anatomical annotations include brain (UBERON:0000955), cerebral cortex, cerebral white matter, corticospinal tract, basal ganglion, thalamus, cerebellum, brainstem and spinal cord. Secondary structures include skeletal muscle, tendon, joint, hip, spine, bone, respiratory tract and gastrointestinal tract. Unilateral lesions commonly produce contralateral hemiplegia; bilateral white-matter lesions often produce diplegia; extensive bilateral cortex/deep-gray injury may produce quadriplegic or dyskinetic CP.

At the subcellular level, implicated compartments include mitochondria (GO:0005739), synapse (GO:0045202), axon (GO:0030424), myelin sheath (GO:0043209), cytoskeleton and lysosome/autophagosome.

8. Temporal development

The causal disturbance occurs prenatally, perinatally, or in early infancy while motor systems are developing. Clinical recognition is usually insidious: abnormal general movements, asymmetry, persistent primitive reflexes, abnormal tone or delayed milestones appear over months. GMA, HINE and MRI can predict CP by 3–6 months corrected age in high-risk infants, although historic diagnosis often occurred around age two in high-income and later in low-resource settings. (klobucka2026evidenceandpractice pages 4-5, lewis2024potentialclinicalapplications pages 1-2)

CP is chronic and lifelong without a conventional staging or remission system. GMFCS motor trajectories are more useful than “disease stages.” The lesion is static, but contracture, hip displacement, scoliosis, pain, fatigue and mobility decline can develop; learning, adaptation and therapy can improve activity and participation. Critical windows include fetal/neonatal neuroprotection and the first years of activity-dependent neuroplasticity.

9. Inheritance and population

Prevalence is generally about 1.5–2 per 1,000 live births globally, with reported ranges exceeding 4 per 1,000 and higher rates in resource-limited settings. A 2020 synthesis reported a ~30% decline in high-income settings to approximately 1.4/1,000, while Bangladesh remained approximately 3.4/1,000. Preterm infants accounted for 43% of cases. (novak2020stateofthe pages 4-6, tegegne2023determinantsofcerebral pages 1-2)

CP overall is multifactorial and does not have one inheritance pattern. Molecular subtypes can be autosomal dominant—often de novo—autosomal recessive, X-linked, mitochondrial, or CNV-mediated. Penetrance, expressivity, germline mosaicism, founder effects and carrier frequency must therefore be stated for the specific diagnosed disorder. Anticipation is not characteristic of CP as a syndrome. Consanguinity increases the probability of recessive CP-like disorders but is not a general cause.

Males are modestly overrepresented in many cohorts; the 2024 WGS cohort was 59.3% male. Biological vulnerability and differential survival may contribute. Socioeconomic and geographic gradients reflect prematurity, infection, neonatal care, ascertainment and rehabilitation access rather than ethnicity as an intrinsic cause. (fehlings2024comprehensivewholegenomesequence pages 21-24, collins2024theimportanceof pages 1-2)

10. Diagnostics

Clinical approach

Diagnosis is clinical: persistent disorder of movement/posture, activity limitation, onset during early development, and a non-progressive causal disturbance. Recommended assessment combines developmental history; neurologic examination; GMA in early infancy; HINE; standardized motor testing; hearing, vision, feeding, communication and cognitive assessment; and GMFCS/MACS/CFCS/EDACS classification. MRI is the principal etiologic imaging study. EEG is used for suspected seizures; EMG is reserved for specific neuromuscular differentials. There is no diagnostic blood test, biopsy or validated circulating biomarker.

Genomic workflow

A pragmatic workflow is: (1) verify phenotype and progression; (2) brain MRI and review pregnancy/perinatal history; (3) genetics referral and trio ES or GS, with CNV detection; (4) CMA if CNVs are not robustly assessed; (5) mtDNA testing, metabolic assays, repeat-expansion, RNA or long-read sequencing when phenotype indicates; (6) periodic reanalysis. Normal MRI, congenital anomalies, dysmorphism, family history, severe intellectual disability/epilepsy, no plausible acquired insult, or an unexpectedly progressive/fluctuating course increase diagnostic suspicion, but absence of these red flags does not exclude a genetic cause. Meta-analytic yields cited in 2024 were ~23% for SNVs and ~5% for CNVs. (silan2025unravellinggeneticetiology pages 1-2, lewis2024potentialclinicalapplications pages 1-2)

Differential diagnosis

Important mimics include hereditary spastic paraplegia (SPAST, ATL1, AP-4 genes), dopa-responsive dystonia, GNAO1 disorders, GLUT1 deficiency, mitochondrial disease, leukodystrophy, spinal muscular/neuromuscular disease, Rett-spectrum disease, neurodegeneration with brain iron accumulation, metabolic disorders and structural spinal disease. Regression, episodic decompensation, progressive weakness/spasticity, neuropathy, organ involvement or MRI evolution should prompt reconsideration.

There is no population newborn screen for CP. High-risk infant follow-up and standardized developmental surveillance constitute targeted early detection. Molecular cascade or reproductive testing applies only after a familial diagnosis.

11. Outcome and prognosis

Most individuals survive into adulthood, but survival varies markedly with gross-motor severity, feeding and respiratory impairment, epilepsy and intellectual disability. Severe HIE has reported mortality of 25–50%, but that statistic concerns the antecedent neonatal syndrome rather than all CP. Modern disease-wide five- and ten-year survival estimates were not available in the retrieved evidence and should not be inferred from HIE cohorts. (collins2024theimportanceof pages 1-2)

Ambulation, communication and self-care are strongly related to GMFCS/MACS/CFCS levels. Major morbidity includes pain, contracture, hip displacement, scoliosis, fractures, aspiration, malnutrition, constipation, epilepsy, sleep disorders and mental-health difficulties. Recovery of destroyed tissue is limited, but neuroplasticity, assistive technology, surgery and environmental accommodations can produce meaningful gains. Prognostic molecular biomarkers are not validated; MRI pattern, HINE, GMA, GMFCS, cognition, feeding safety and epilepsy currently carry greater clinical utility.

12. Treatment

There is no single disease-modifying cure. Management should be individualized, family-centered, goal-directed and multidisciplinary.

Established interventions

• Rehabilitation: active, intensive, task-specific practice; goal-directed training; home programs; bimanual training; constraint-induced movement therapy; strength/fitness and treadmill training; mobility, communication, feeding, occupational and speech therapy. Passive, non-goal-directed treatment is less effective. (novak2020stateofthe pages 13-14, klobucka2026evidenceandpractice pages 4-5)
• Spasticity/dystonia: oral baclofen, diazepam or selected alternatives; focal botulinum toxin A with active therapy/casting; intrathecal baclofen for selected generalized hypertonia. Drugs reduce symptoms but may cause weakness, sedation, dysphagia or systemic adverse effects.
• Epilepsy/pain/bone and GI care: indication-specific antiseizure medication, analgesia, bisphosphonates in selected low-bone-density cases, nutrition and reflux/constipation management.
• Surgery: selective dorsal rhizotomy for carefully selected spastic diplegia; orthopedic soft-tissue/bony procedures for contracture, hip displacement and gait; scoliosis correction; gastrostomy when safe nutrition cannot otherwise be maintained. Hip surveillance uses serial clinical examination and radiographic migration percentage. (klobucka2026evidenceandpractice pages 12-13)

Suggested NCIT intervention annotations include Physical Therapy, Occupational Therapy, Speech Therapy, Botulinum Toxin, Baclofen, Intrathecal Drug Administration, Selective Dorsal Rhizotomy, Orthopedic Surgery, Gastrostomy and Assistive Device.

No CP-specific CPIC pharmacogenomic algorithm is established. Genotype-guided treatment becomes relevant when testing reclassifies the phenotype—for example, a treatable neurotransmitter, transporter or metabolic disorder.

Experimental therapies and trials

Stem cells, conditioned medium, non-invasive neuromodulation, robotic devices and other regenerative approaches remain investigational. They should not be marketed as proven restoration.

• NCT06586437: randomized, double-masked study of cortical/spinal transcutaneous current stimulation with imaging and neurophysiology; estimated n=50, active-not-recruiting. (NCT06586437 chunk 1)
• NCT05158218: robotic exoskeleton gait training versus conventional gait therapy, 24 sessions over eight weeks; randomized, assessor-masked, n=64, active-not-recruiting. (NCT05158218 chunk 1)
• NCT04360395: eight-week gait therapy with MEG/EEG, MRI and H-reflex characterization of responders; n=120, active-not-recruiting. (NCT04360395 chunk 1)
• NCT04314687: phase 1/2 randomized trial of intrathecal allogeneic umbilical-cord mesenchymal stromal cells with or without conditioned medium versus physiotherapy; n=78, active-not-recruiting. (NCT04314687 chunk 1)

Hyperbaric oxygen, craniosacral manipulation, unstructured sensory integration and passive stretching without task goals lack convincing evidence. (klobucka2026evidenceandpractice pages 12-13)

13. Prevention

Primary prevention: optimize maternal health and vaccination; reduce smoking/substance exposure; prevent and treat maternal infection; prevent medically avoidable prematurity; use antenatal corticosteroids and magnesium sulfate when indicated; ensure safe obstetric and neonatal care. Magnesium sulfate and therapeutic hypothermia have the clearest CP-specific neuroprotective evidence. (novak2020stateofthe pages 4-6)

Secondary prevention: identify high-risk infants using neonatal history, MRI/ultrasound, GMA and HINE; initiate early active intervention before a delayed definitive label; promptly treat seizures, jaundice, hypoglycemia and infection.

Tertiary prevention: hip surveillance, nutrition/aspiration management, vaccination, epilepsy care, bone-health monitoring, contracture prevention, communication support and accessible participation. Genetic counseling should explain that recurrence may be low after a de novo variant, 25% for many recessive diagnoses, 50% for some dominant diagnoses, or follow maternal mitochondrial inheritance—but only after variant-specific interpretation.

14. Other species and natural disease

CP is a human clinical construct; there is no single established naturally occurring veterinary equivalent with a CP-specific breed ontology. Animals can naturally sustain congenital malformations, neonatal hypoxia, stroke or infection and show non-progressive motor impairment, but calling these cases “cerebral palsy” is generally analogical. There is no transmission or zoonotic potential.

Relevant taxa for comparative studies include mouse (Mus musculus, NCBI Taxon 10090), rat (Rattus norvegicus, 10116), rabbit (Oryctolagus cuniculus, 9986), sheep (Ovis aries, 9940), pig (Sus scrofa, 9823), and rhesus macaque (Macaca mulatta, 9544). Orthologs of causal human genes are studied in species-specific databases; their relevance depends on the molecular subtype.

15. Model organisms

• Rodent Rice–Vannucci HI model: unilateral carotid ligation plus systemic hypoxia in neonatal mice/rats. Advantages are cost, genetic manipulation and molecular assays; limitations are unilateral, variably infarct-like injury and a small, lissencephalic, relatively white-matter-poor brain. (koehler2018perinatalhypoxicischemicbrain pages 1-2)
• Perinatal rabbit HI: produces hypertonia, postural and locomotor abnormalities resembling CP; useful for motor-phenotype studies but less genetically tractable.
• Fetal sheep: umbilical-cord occlusion or cerebral hypoperfusion; particularly useful for pre-oligodendrocyte vulnerability, white-matter injury and continuous fetal physiology.
• Newborn piglet: gyrencephalic brain and human-like gray/white-matter organization; hypoxia/hypoperfusion reproduces term-HIE systems injury and permits intensive-care monitoring.
• Non-human primate: partial asphyxia preferentially affects motor/somatosensory cortex, basal ganglia and thalamus, while complete asphyxia more strongly injures cerebellum, brainstem sensory nuclei and thalamus. Fidelity is high, but cost and ethical constraints are substantial. (koehler2018perinatalhypoxicischemicbrain pages 1-2)
• Maternal-immune-activation plus HI models: capture gene/environment and infection/hypoxia “two-hit” biology. Model validity depends critically on inflammatory stimulus, dose, developmental timing and HI severity. (collins2024theimportanceof pages 1-2)
• Genetic/cellular systems: knockout/knock-in animals, patient iPSC-derived neurons/glia, neural organoids and CRISPR-edited lines can test specific CP-associated variants, but cannot reproduce the full motor, placental and developmental context.

Animal work provided decisive translational support for neonatal hypothermia, illustrating the value of physiological large-animal models. No model reproduces the complete etiologic and phenotypic heterogeneity of human CP. (koehler2018perinatalhypoxicischemicbrain pages 1-2)

Key 2023–2024 sources and exact abstract statements

1. Fehlings et al., Nature Genetics, March 2024. “Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.” DOI/URL: https://doi.org/10.1038/s41588-024-01686-x. This primary human trio-WGS study is the strongest recent genomic evidence retrieved. (fehlings2024comprehensivewholegenomesequence pages 26-28, fehlings2024comprehensivewholegenomesequence pages 17-19)
2. Lewis et al., eBioMedicine, August 2024. Exact summary: “Recent advancements in genomic technologies offer additional opportunities to uncover variations in human genomes, transcriptomes, and epigenomes that have previously escaped detection.” DOI/URL: https://doi.org/10.1016/j.ebiom.2024.105229. (lewis2024potentialclinicalapplications pages 1-2)
3. Xu et al., Neural Regeneration Research, September 2024. Exact abstract statement: “It is now widely acknowledged that genetic mutations and alterations play a pivotal role in cerebral palsy development, which can be further influenced by environmental factors.” DOI/URL: https://doi.org/10.4103/1673-5374.385855. (xu2024geneticpathwaysin pages 1-1)
4. Tegegne, Sudanese Journal of Paediatrics, 2023. Exact abstract statement: “The commonest determinants of CP in children are premature babies and low weight, low Apgar scores, intrauterine infection, congenital brain malformations, thyroid disease, premature rupture of membrane (PROM) and placental abruption.” DOI/URL: https://doi.org/10.24911/SJP.106-1670589241. (tegegne2023determinantsofcerebral pages 1-2)
5. Collins et al., Biomedicines, published 8 November 2024. Exact abstract statement: “The only proven therapy for HIE is therapeutic hypothermia.” DOI/URL: https://doi.org/10.3390/biomedicines12112559. (collins2024theimportanceof pages 1-2)

Evidence limitations

The strongest retrieved evidence supports definition, broad prevalence, genomic yield, MRI patterns, risk factors, neuroprotective interventions and selected rehabilitation approaches. Exact modern life-expectancy estimates, phenotype-specific quality-of-life effect sizes, validated CP-wide metabolomic/proteomic signatures, protective genetic alleles, and complete HGNC/OMIM/ClinVar variant-level mappings were not established in the retrieved corpus. Such fields should remain null or be populated only through a variant- or registry-specific curation rather than extrapolation.

References

1. (xu2024geneticpathwaysin pages 1-1): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.

2. (fehlings2024comprehensivewholegenomesequence pages 26-28): Darcy L. Fehlings, Mehdi Zarrei, Worrawat Engchuan, Neal Sondheimer, Bhooma Thiruvahindrapuram, Jeffrey R. MacDonald, Edward J. Higginbotham, Ritesh Thapa, Tarannum Behlim, Sabrina Aimola, Lauren Switzer, Pamela Ng, John Wei, Prakroothi S. Danthi, Giovanna Pellecchia, Sylvia Lamoureux, Karen Ho, Sergio L. Pereira, Jill de Rijke, Wilson W. L. Sung, Alireza Mowjoodi, Jennifer L. Howe, Thomas Nalpathamkalam, Roozbeh Manshaei, Siavash Ghaffari, Joseph Whitney, Rohan V. Patel, Omar Hamdan, Rulan Shaath, Brett Trost, Shannon Knights, Dawa Samdup, Anna McCormick, Carolyn Hunt, Adam Kirton, Anne Kawamura, Ronit Mesterman, Jan Willem Gorter, Nomazulu Dlamini, Daniele Merico, Murto Hilali, Kyle Hirschfeld, Kritika Grover, Nelson X. Bautista, Kara Han, Christian R. Marshall, Ryan K. C. Yuen, Padmaja Subbarao, Meghan B. Azad, Stuart E. Turvey, Piush Mandhane, Theo J. Moraes, Elinor Simons, George Maxwell, Michael Shevell, Gregory Costain, Jacques L. Michaud, Fadi F. Hamdan, Julie Gauthier, Kevin Uguen, Dimitri J. Stavropoulos, Richard F. Wintle, Maryam Oskoui, and Stephen W. Scherer. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics, 56:585-594, Mar 2024. URL: https://doi.org/10.1038/s41588-024-01686-x, doi:10.1038/s41588-024-01686-x. This article has 43 citations and is from a highest quality peer-reviewed journal.

3. (fehlings2024comprehensivewholegenomesequence pages 17-19): Darcy L. Fehlings, Mehdi Zarrei, Worrawat Engchuan, Neal Sondheimer, Bhooma Thiruvahindrapuram, Jeffrey R. MacDonald, Edward J. Higginbotham, Ritesh Thapa, Tarannum Behlim, Sabrina Aimola, Lauren Switzer, Pamela Ng, John Wei, Prakroothi S. Danthi, Giovanna Pellecchia, Sylvia Lamoureux, Karen Ho, Sergio L. Pereira, Jill de Rijke, Wilson W. L. Sung, Alireza Mowjoodi, Jennifer L. Howe, Thomas Nalpathamkalam, Roozbeh Manshaei, Siavash Ghaffari, Joseph Whitney, Rohan V. Patel, Omar Hamdan, Rulan Shaath, Brett Trost, Shannon Knights, Dawa Samdup, Anna McCormick, Carolyn Hunt, Adam Kirton, Anne Kawamura, Ronit Mesterman, Jan Willem Gorter, Nomazulu Dlamini, Daniele Merico, Murto Hilali, Kyle Hirschfeld, Kritika Grover, Nelson X. Bautista, Kara Han, Christian R. Marshall, Ryan K. C. Yuen, Padmaja Subbarao, Meghan B. Azad, Stuart E. Turvey, Piush Mandhane, Theo J. Moraes, Elinor Simons, George Maxwell, Michael Shevell, Gregory Costain, Jacques L. Michaud, Fadi F. Hamdan, Julie Gauthier, Kevin Uguen, Dimitri J. Stavropoulos, Richard F. Wintle, Maryam Oskoui, and Stephen W. Scherer. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics, 56:585-594, Mar 2024. URL: https://doi.org/10.1038/s41588-024-01686-x, doi:10.1038/s41588-024-01686-x. This article has 43 citations and is from a highest quality peer-reviewed journal.

4. (lewis2024potentialclinicalapplications pages 1-2): Sara A. Lewis, Andrew Ruttenberg, Tuğçe Iyiyol, Nahyun Kong, Sheng Chih Jin, and Michael C. Kruer. Potential clinical applications of advanced genomic analysis in cerebral palsy. Aug 2024. URL: https://doi.org/10.1016/j.ebiom.2024.105229, doi:10.1016/j.ebiom.2024.105229. This article has 5 citations and is from a peer-reviewed journal.

5. (OpenTargets Search: cerebral palsy): Open Targets Query (cerebral palsy, 34 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (xu2024geneticpathwaysin pages 2-3): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.

7. (novak2020stateofthe pages 4-6): Iona Novak, Catherine Morgan, Michael Fahey, Megan Finch-Edmondson, Claire Galea, Ashleigh Hines, Katherine Langdon, Maria Mc Namara, Madison CB Paton, Himanshu Popat, Benjamin Shore, Amanda Khamis, Emma Stanton, Olivia P Finemore, Alice Tricks, Anna te Velde, Leigha Dark, Natalie Morton, and Nadia Badawi. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Current Neurology and Neuroscience Reports, Feb 2020. URL: https://doi.org/10.1007/s11910-020-1022-z, doi:10.1007/s11910-020-1022-z. This article has 1632 citations and is from a domain leading peer-reviewed journal.

8. (silan2025unravellinggeneticetiology pages 1-2): Ula Arkar Silan, Ana Trebše, Jernej Kovač, Mihael Rogac, Anja Troha Gergeli, Robert Šket, Tina Bregant, David Neubauer, Borut Peterlin, and Damjan Osredkar. Unravelling genetic etiology of cerebral palsy: findings from a slovenian pediatric cohort. Frontiers in Neurology, Jul 2025. URL: https://doi.org/10.3389/fneur.2025.1615449, doi:10.3389/fneur.2025.1615449. This article has 1 citations and is from a peer-reviewed journal.

9. (tegegne2023determinantsofcerebral pages 1-2): Kaleab Tegegne. Determinants of cerebral palsy in children: systematic review. Sudanese journal of paediatrics, 23 2:126-144, Jan 2023. URL: https://doi.org/10.24911/sjp.106-1670589241, doi:10.24911/sjp.106-1670589241. This article has 13 citations.

10. (collins2024theimportanceof pages 1-2): Bailey Collins, Elise A. Lemanski, and Elizabeth Wright-Jin. The importance of including maternal immune activation in animal models of hypoxic–ischemic encephalopathy. Biomedicines, 12:2559, Nov 2024. URL: https://doi.org/10.3390/biomedicines12112559, doi:10.3390/biomedicines12112559. This article has 8 citations.

11. (klobucka2026evidenceandpractice pages 4-5): Stanislava Klobucká, Katarína Chamutyová, Robert Klobucký, Pavel Šiarnik, Ľudmila Podracká, and Branislav Kollár. Evidence and practice in the rehabilitation of patients with cerebral palsy: a structured narrative review informed by a systematic literature search. Bratislava Medical Journal, 127:1790-1812, Mar 2026. URL: https://doi.org/10.1007/s44411-026-00551-z, doi:10.1007/s44411-026-00551-z. This article has 2 citations.

12. (fehlings2024comprehensivewholegenomesequence pages 21-24): Darcy L. Fehlings, Mehdi Zarrei, Worrawat Engchuan, Neal Sondheimer, Bhooma Thiruvahindrapuram, Jeffrey R. MacDonald, Edward J. Higginbotham, Ritesh Thapa, Tarannum Behlim, Sabrina Aimola, Lauren Switzer, Pamela Ng, John Wei, Prakroothi S. Danthi, Giovanna Pellecchia, Sylvia Lamoureux, Karen Ho, Sergio L. Pereira, Jill de Rijke, Wilson W. L. Sung, Alireza Mowjoodi, Jennifer L. Howe, Thomas Nalpathamkalam, Roozbeh Manshaei, Siavash Ghaffari, Joseph Whitney, Rohan V. Patel, Omar Hamdan, Rulan Shaath, Brett Trost, Shannon Knights, Dawa Samdup, Anna McCormick, Carolyn Hunt, Adam Kirton, Anne Kawamura, Ronit Mesterman, Jan Willem Gorter, Nomazulu Dlamini, Daniele Merico, Murto Hilali, Kyle Hirschfeld, Kritika Grover, Nelson X. Bautista, Kara Han, Christian R. Marshall, Ryan K. C. Yuen, Padmaja Subbarao, Meghan B. Azad, Stuart E. Turvey, Piush Mandhane, Theo J. Moraes, Elinor Simons, George Maxwell, Michael Shevell, Gregory Costain, Jacques L. Michaud, Fadi F. Hamdan, Julie Gauthier, Kevin Uguen, Dimitri J. Stavropoulos, Richard F. Wintle, Maryam Oskoui, and Stephen W. Scherer. Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics, 56:585-594, Mar 2024. URL: https://doi.org/10.1038/s41588-024-01686-x, doi:10.1038/s41588-024-01686-x. This article has 43 citations and is from a highest quality peer-reviewed journal.

13. (yigit2026unmaskinggeneticetiologies pages 1-2): Ayca Yigit, Ozlem Akgun-Dogan, Zeynep Ozkeserli, Gunseli Bayram Akcapınar, Semih Ayta, Pinar Gencpinar, Hulya Maras Genc, Busra Kutlubay, Bulent Kara, Hatice Gulhan Sozen, Nihat Bugra Agaoglu, Ozkan Ozdemir, Kaya Bilguvar, and Ugur Ozbek. Unmasking genetic etiologies in neurodevelopmental disorders characterized by cerebral palsy: insights from integrative genomic approaches. Frontiers in Neurology, Feb 2026. URL: https://doi.org/10.3389/fneur.2026.1742186, doi:10.3389/fneur.2026.1742186. This article has 0 citations and is from a peer-reviewed journal.

14. (koehler2018perinatalhypoxicischemicbrain pages 1-2): Raymond C Koehler, Zeng-Jin Yang, Jennifer K Lee, and Lee J Martin. Perinatal hypoxic-ischemic brain injury in large animal models: relevance to human neonatal encephalopathy. Journal of Cerebral Blood Flow & Metabolism, 38:2092-2111, Aug 2018. URL: https://doi.org/10.1177/0271678x18797328, doi:10.1177/0271678x18797328. This article has 109 citations and is from a highest quality peer-reviewed journal.

15. (novak2020stateofthe pages 13-14): Iona Novak, Catherine Morgan, Michael Fahey, Megan Finch-Edmondson, Claire Galea, Ashleigh Hines, Katherine Langdon, Maria Mc Namara, Madison CB Paton, Himanshu Popat, Benjamin Shore, Amanda Khamis, Emma Stanton, Olivia P Finemore, Alice Tricks, Anna te Velde, Leigha Dark, Natalie Morton, and Nadia Badawi. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Current Neurology and Neuroscience Reports, Feb 2020. URL: https://doi.org/10.1007/s11910-020-1022-z, doi:10.1007/s11910-020-1022-z. This article has 1632 citations and is from a domain leading peer-reviewed journal.

16. (klobucka2026evidenceandpractice pages 12-13): Stanislava Klobucká, Katarína Chamutyová, Robert Klobucký, Pavel Šiarnik, Ľudmila Podracká, and Branislav Kollár. Evidence and practice in the rehabilitation of patients with cerebral palsy: a structured narrative review informed by a systematic literature search. Bratislava Medical Journal, 127:1790-1812, Mar 2026. URL: https://doi.org/10.1007/s44411-026-00551-z, doi:10.1007/s44411-026-00551-z. This article has 2 citations.

17. (NCT06586437 chunk 1): Max Kurz. Neuromodulation of the Cortex and Spinal Cord. Father Flanagan's Boys' Home. 2024. ClinicalTrials.gov Identifier: NCT06586437

18. (NCT05158218 chunk 1): Max Kurz. Robotic Exoskeleton Gait Training in Adolescents With Cerebral Palsy. Father Flanagan's Boys' Home. 2021. ClinicalTrials.gov Identifier: NCT05158218

19. (NCT04360395 chunk 1): Max Kurz. Igniting Mobility in Adolescents and Young Adults With Cerebral Palsy. Father Flanagan's Boys' Home. 2020. ClinicalTrials.gov Identifier: NCT04360395

20. (NCT04314687 chunk 1): Stem Cell and Conditioned Medium for Cerebral Palsy. PT. Prodia Stem Cell Indonesia. 2021. ClinicalTrials.gov Identifier: NCT04314687

21. (xu2024geneticpathwaysin pages 8-9): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.

22. (xu2024geneticpathwaysin pages 9-9): Yiran Xu, Yifei Li, Seidu A. Richard, Yanyan Sun, and Changlian Zhu. Genetic pathways in cerebral palsy: a review of the implications for precision diagnosis and understanding disease mechanisms. Neural Regeneration Research, 19:1499-1508, Sep 2024. URL: https://doi.org/10.4103/1673-5374.385855, doi:10.4103/1673-5374.385855. This article has 15 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00